$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2023 Q3 Form 10-Q Financial Statement

#000147793223005935 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $6.000K $0.00 $0.00
YoY Change -89.09% -100.0%
Cost Of Revenue $2.400K $0.00 $0.00
YoY Change -85.0% -100.0%
Gross Profit $3.600K $0.00 $0.00
YoY Change -90.77% -100.0%
Gross Profit Margin 60.0%
Selling, General & Admin $531.0K $859.5K $1.108M
YoY Change -34.07% -22.45% 122.43%
% of Gross Profit 14751.17%
Research & Development $992.7K $309.5K $659.7K
YoY Change 329.86% -53.09%
% of Gross Profit 27575.61%
Depreciation & Amortization $20.00K $23.02K $23.02K
YoY Change -13.12% 0.0% 0.0%
% of Gross Profit 555.56%
Operating Expenses $1.547M $1.192M $1.791M
YoY Change 46.0% -33.45% 243.56%
Operating Profit -$1.543M -$1.192M -$1.791M
YoY Change 51.23% -33.45% 247.23%
Interest Expense $90.00K $89.91K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $89.23K $89.91K $0.00
YoY Change 134.31% -100.0%
Pretax Income -$1.454M -$1.102M -$1.791M
YoY Change 48.01% -38.47% -38.35%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.454M -$1.102M -$1.791M
YoY Change 48.01% -38.47% -38.35%
Net Earnings / Revenue -24232.53%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$1.02 -$0.78 -$0.20
COMMON SHARES
Basic Shares Outstanding 1.431M shares 14.08M shares 9.011M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.510M $3.990M $22.86M
YoY Change -73.42% -82.55% 14316.84%
Cash & Equivalents $4.507M $3.990M $22.86M
Short-Term Investments
Other Short-Term Assets $7.530M $9.735M $64.96K
YoY Change 49.96% 14885.99%
Inventory $7.794K $10.19K $20.63K
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $12.04M $13.73M $22.95M
YoY Change -45.27% -40.15% 14370.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $3.280K $3.280K
YoY Change -100.0% 0.0%
Total Long-Term Assets $469.8K $392.8K $484.9K
YoY Change 1.71% -18.99% -15.48%
TOTAL ASSETS
Total Short-Term Assets $12.04M $13.73M $22.95M
Total Long-Term Assets $469.8K $392.8K $484.9K
Total Assets $12.51M $14.13M $23.43M
YoY Change -44.31% -39.71% 3100.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $367.0K $344.4K $310.7K
YoY Change 11.96% 10.86% -14.89%
Accrued Expenses $39.92K $39.92K $64.92K
YoY Change -27.31% -38.51% -9.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $421.2K $398.5K $389.8K
YoY Change 6.1% 2.24% -73.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $421.2K $398.5K $389.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $421.2K $398.5K $389.8K
YoY Change 6.1% 2.24% -73.06%
SHAREHOLDERS EQUITY
Retained Earnings -$57.42M -$55.97M -$46.61M
YoY Change 20.64% 20.06% 26.12%
Common Stock $1.431K $1.431K $13.96K
YoY Change -89.83% -89.75% -98.86%
Preferred Stock
YoY Change
Treasury Stock (at cost) $191.8K
YoY Change
Treasury Stock Shares
Shareholders Equity $12.09M $13.73M $23.04M
YoY Change
Total Liabilities & Shareholders Equity $12.51M $14.13M $23.43M
YoY Change -44.31% -39.71% 3100.04%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$1.454M -$1.102M -$1.791M
YoY Change 48.01% -38.47% -38.35%
Depreciation, Depletion And Amortization $20.00K $23.02K $23.02K
YoY Change -13.12% 0.0% 0.0%
Cash From Operating Activities -$1.300M -$986.7K -$1.756M
YoY Change 48.86% -43.79% 690.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.820M -$4.540M $0.00
YoY Change -136.25%
Cash From Investing Activities $1.820M -$4.540M $0.00
YoY Change -136.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 15.47M
YoY Change -100.0% -100.0% 14553.11%
NET CHANGE
Cash From Operating Activities -1.300M -986.7K -1.756M
Cash From Investing Activities 1.820M -4.540M 0.000
Cash From Financing Activities 0.000 0.000 15.47M
Net Change In Cash 520.0K -5.527M 13.72M
YoY Change -108.82% -140.29% -11868.92%
FREE CASH FLOW
Cash From Operating Activities -$1.300M -$986.7K -$1.756M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1407625 shares
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1431127 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1431126 shares
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55965906 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53811858 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13728950 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14127477 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19186326 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
309480 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
659695 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1192038 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1791144 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1192038 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1791144 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2305108 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15864674 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001187953
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
22970 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53500
dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0622284
dei Entity Address Address Line1
EntityAddressAddressLine1
211 E Osborn Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Phoenix
dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85012
dei City Area Code
CityAreaCode
480
dei Local Phone Number
LocalPhoneNumber
399-2822
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CELZ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1430530 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1407624 shares
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
628509 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
859537 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1108428 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1630557 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46042 usd
us-gaap Operating Expenses
OperatingExpenses
2305108 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
89913 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
0 usd
us-gaap Interest Income Other
InterestIncomeOther
151060 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
89913 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
151060 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1102125 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1791144 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2154048 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1102125 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1791144 usd
us-gaap Net Income Loss
NetIncomeLoss
-2154048 usd
CY2023Q2 celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-0.78
CY2022Q2 celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-1.99
celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-1.53
CY2023Q2 celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1409948 shares
CY2022Q2 celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
901125 shares
celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1408793 shares
us-gaap Profit Loss
ProfitLoss
2154048 usd
us-gaap Profit Loss
ProfitLoss
2946013 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18324 usd
us-gaap Share Based Compensation
ShareBasedCompensation
50422 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46042 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46042 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2485 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9759 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-184428 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64960 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2923125 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-451181 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
40535 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4828379 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3332429 usd
us-gaap Payments For Deposits On Real Estate Acquisitions
PaymentsForDepositsOnRealEstateAcquisitions
4551049 usd
us-gaap Payments For Deposits On Real Estate Acquisitions
PaymentsForDepositsOnRealEstateAcquisitions
0 usd
celz Proceeds From Redemptions Of Certificates Of Deposit
ProceedsFromRedemptionsOfCertificatesOfDeposit
5048459 usd
celz Proceeds From Redemptions Of Certificates Of Deposit
ProceedsFromRedemptionsOfCertificatesOfDeposit
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
497410 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
celz Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
celz Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
15471775 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
445 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15472220 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4330969 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12139791 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8320519 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10723870 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3989550 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863661 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
9186 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
celz Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
0 usd
celz Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
250000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15864674 usd
celz Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18324 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13728950 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14821913 usd
CY2023Q2 celz Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
9162 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1102125 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13728950 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10217740 usd
celz Stock Issued During Period Value Common Stock And Accompanying Warrants Net Of Issuance Costs Shares
StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares
15471775 usd
celz Common Stock Issued For Related Party Patent Liabilities Amount
CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount
250000 usd
celz Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
445 usd
us-gaap Share Based Compensation
ShareBasedCompensation
50422 usd
us-gaap Net Income Loss
NetIncomeLoss
-2946013 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23044369 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9354231 usd
CY2022Q2 celz Stock Issued During Period Value Common Stock And Accompanying Warrants Net Of Issuance Costs Amount
StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount
15471775 usd
CY2022Q2 celz Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
445 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
9062 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1791144 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23044369 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Use of Estimates –</em></strong>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
40000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Concentration Risks</strong></em> – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions.</p>
CY2023Q2 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2016Q1 celz No Of Share Exchange
NoOfShareExchange
43112 shares
CY2016Q1 celz Restricted Common Stock
RestrictedCommonStock
100000 usd
CY2023Q2 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
26030 usd
celz Expected Amount Of Amortization
ExpectedAmountOfAmortization
9972 usd
CY2017Q2 celz Payments Upon Completion Of Irb Clinical Trial
PaymentsUponCompletionOfIrbClinicalTrial
200000 usd
CY2017Q2 celz Payments In The Event Of Commercialization Of Technology
PaymentsInTheEventOfCommercializationOfTechnology
300000 usd
CY2023Q2 celz Company Paid
CompanyPaid
50000 usd
CY2020Q4 celz Common Stock Issue
CommonStockIssue
667 usd
CY2020Q4 celz Company Paid
CompanyPaid
50000 usd
CY2020Q4 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 usd
CY2021Q3 celz Company Paid
CompanyPaid
40000 usd
CY2021Q3 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 usd
CY2021Q3 celz Common Stock Issue
CommonStockIssue
8466 usd
CY2021Q1 celz Company Paid
CompanyPaid
50000 usd
CY2021Q1 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 usd
CY2021Q1 celz Common Stock Issue
CommonStockIssue
8929 usd
CY2023Q2 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
22970 usd
CY2020Q4 celz Common Stock Issue
CommonStockIssue
133404 usd
CY2020Q4 celz License Agreement Description
LicenseAgreementDescription
(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
CY2020Q4 celz License Fees
LicenseFees
250000 usd
CY2022Q1 celz Number Of Share Issuance Of Common Stock To Jadi Cell
NumberOfShareIssuanceOfCommonStockToJadiCell
18018 shares
CY2022Q4 celz Licensing Agreements
LicensingAgreements
760000 usd
CY2022Q4 celz Accumulated Amortization Beginning Balance
AccumulatedAmortizationBeginningBalance
-324405 usd
celz Accumulated Amortization Addition Of New Assets
AccumulatedAmortizationAdditionOfNewAssets
0 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 usd
celz Accumulated Amortization
AccumulatedAmortization
-46042 usd
CY2023Q2 celz Licensing Agreements Beginning Balance
LicensingAgreementsBeginningBalance
760000 usd
CY2023Q2 celz Accumulated Amortization Ending Balance
AccumulatedAmortizationEndingBalance
-370447 usd
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
299167 shares
CY2022Q2 celz Purchase Of Warrants Shares
PurchaseOfWarrantsShares
456389 shares
CY2022Q2 celz Purchase Of Pre Funded Warrant And Related Common Warrant
PurchaseOfPreFundedWarrantAndRelatedCommonWarrant
1511112 shares
CY2022Q2 celz Combined Offering Price Of Pre Funded Warrant And Related Common Warrant
CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant
22.50
CY2022Q2 celz Description Of Amendment
DescriptionOfAmendment
pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
celz Pre Funded Warrants Exercise Price
PreFundedWarrantsExercisePrice
0.001
CY2023Q2 celz Repurchase Of Stock
RepurchaseOfStock
2000000 shares
celz Common Warrants Exercise Price
CommonWarrantsExercisePrice
20.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0081 pure
us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.9295 pure
CY2023Q2 us-gaap Share Price
SharePrice
18.30
CY2022Q4 celz Initial Payment Amount
InitialPaymentAmount
2000000 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000000 usd

Files In Submission

Name View Source Status
0001477932-23-005935-index-headers.html Edgar Link pending
0001477932-23-005935-index.html Edgar Link pending
0001477932-23-005935.txt Edgar Link pending
0001477932-23-005935-xbrl.zip Edgar Link pending
celz-20230630.xsd Edgar Link pending
celz_10q.htm Edgar Link pending
celz_10qimg2.jpg Edgar Link pending
celz_ex311.htm Edgar Link pending
celz_ex312.htm Edgar Link pending
celz_ex321.htm Edgar Link pending
celz_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
celz-20230630_def.xml Edgar Link unprocessable
celz-20230630_cal.xml Edgar Link unprocessable
celz-20230630_lab.xml Edgar Link unprocessable
celz-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
celz_10q_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending